Acceleron Presents Encouraging Response Rates and Progression-Free Survival Data in Patients with Advanced Renal Cell Carcinoma

Acceleron Pharma has reported new preliminary data from the DART study, an ongoing Phase II clinical trial of dalantercept in patients with advanced renal cell carcinoma (RCC). The preliminary data from part 1 of the DART study were presented in an oral session at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium held in Orlando, Florida on February 28, 2015.

“These promising response rates and progression-free survival data suggest that the dual angiogenesis blockade of ALK1 and VEGFR signaling with dalantercept and axitinib may provide additive efficacy compared to VEGFR inhibitor therapy alone,” said Matthew Sherman, Chief Medical Officer of Acceleron.

“The results from part 1 of this study provide encouraging evidence of the safety and activity of this combination of two distinct anti-angiogenic agents in previously treated patients with advanced RCC,” said Martin H. Voss, medical oncologist at Memorial Sloan Kettering Cancer Center and lead investigator for the trial. “We look forward to building on these results in the randomized part 2 of the ongoing DART trial.”

In the DART trial, dalantercept, an activin receptor-like kinase 1 (ALK1) inhibitor, is being evaluated in combination with Inlyta (axitinib), a VEGFR tyrosine kinase inhibitor, in patients with advanced RCC who have progressed on one prior VEGFR tyrosine kinase inhibitor and no more than three prior treatments.